Neurology · Baltimore area, MD
Neurology studies in Baltimore area, MD
52 recruiting studies have a site in the Baltimore area. This page includes nearby cities such as Towson, Columbia, Glen Burnie, Ellicott City.
52 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
First-in-Human Single and Multiple Dose of HL-400
Highlightll Pharmaceutical (USA) LLC
- Location
- Baltimore, MD
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
PRG Science & Technology Co., Ltd.
- Location
- Baltimore, MD
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 2Overnight stay mentioned
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
National Institute on Aging (NIA)
- Location
- Baltimore, MD
- Eligibility basics
- Ages 65–120
- RecruitingHealthy volunteersPhase 1
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
University of Maryland, Baltimore
- Location
- Baltimore, MD
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Lutherville, MD + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
- Location
- Baltimore, MD + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
argenx
- Location
- Columbia, MD + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A/S
- Location
- Baltimore, MD + 13 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Baltimore, MD + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Baltimore, MD + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Alnylam Pharmaceuticals
- Location
- Baltimore, MD + 9 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Prilenia
- Location
- Baltimore, MD + 17 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Baltimore, MD + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Supernus Pharmaceuticals, Inc.
- Location
- Baltimore, MD + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2/Phase 3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Janssen Research & Development, LLC
- Location
- Baltimore, MD + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Insmed Gene Therapy LLC
- Location
- Baltimore, MD + 6 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Baltimore, MD + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Corxel Pharmaceuticals
- Location
- Baltimore, MD + 19 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Baltimore, MD + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Pivotal Study of N-acetyl-L-leucine for CACNA1A
IntraBio Inc
- Location
- Baltimore, MD + 2 other US sites
- Eligibility basics
- Ages 4+
- Recruiting
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
SetPoint Medical Corporation
- Location
- Baltimore, MD + 8 other US sites
- Eligibility basics
- Ages 22–60
- RecruitingPhase 1/Phase 2
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
UniQure Biopharma B.V.
- Location
- Baltimore, MD + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Baltimore, MD + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics
- Location
- Baltimore, MD + 33 other US sites
- Eligibility basics
- Ages 45–75
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.